Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM - PACE-CME

Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

A positive view on a negative trial with DOAC after TAVR
A positive view on a negative trial with DOAC after TAVR
ACC.22
A positive view on a negative trial with DOAC after TAVR
- Megan Coylewright, MD
EHR-based intervention improves quality care for patients with HF
EHR-based intervention improves quality care for patients with HF
ACC.22
EHR-based intervention improves quality care for patients with HF
- Tariq Ahmad, MD
A first clinical trial testing the use of an H₂S donor after heart attack
A first clinical trial testing the use of an H₂S donor after heart attack
ACC.22
A first clinical trial testing the use of an H₂S donor after heart attack
- Marie-Sophie de Koning, MD
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
ACC.22
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
- Florian Rader, MD